Motilal Oswal's research report on Polycab India: Polycab India (Polycab)’s 4QFY24 performance was ahead of our estimates. It reported an EBITDA of INR7.6b (15% above our est.) led by higher revenue growth (12% above est.) and a better margin in the cables & wires segment (15.1% vs. estimated 14.3%). Profit stood at INR5.5b vs. est. of INR4.7b.
Open FlipMotilal Oswal's research report on Aurobindo PharmaWe analyzed the biosimilar portfolio of Aurobindo Pharma (ARBP) to understand the progress as well as competitive dynamics for each product. ARBP has built a biosimilar pipeline, which is expected to provide commercial benefit from FY26/FY27 onwards. It remains among the leading companies to gain traction in certain biosimilar products.
Open FlipMotilal Oswal's research report on TCI Express: TCI Express (TCIE)’s 4QFY24 revenue decreased 3% YoY to ~INR3.2b (in line), while volumes declined 2% YoY in 4QFY24. The persistent challenges of subdued demand, especially in the lifestyle product segment, and elevated inventory levels at the customer-end led to slower dispatches for the quarter.
Open Flip